EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pediatric Outpatient Fluoroquinolone Dispensing After EMA/AIFA Safety Restrictions: A Regional Interrupted Time-Series Analysis from Southern Italy

Maurizio Aricò, Cataldo Procacci, Pasquale Stefanizzi, Claudia Palmieri, Silvio Tafuri

Antibiotics · 18.11.2026 · 15 (11) · 1151

DOI: 10.3390/antibiotics15111151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 18.11.2026. Verfasst von Maurizio Aricò und 4 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Pediatric fluoroquinolone use is restricted because of safety concerns and antimicrobial-stewardship priorities. We described outpatient dispensing trends in Apulia, Italy, during 2019–2024 and examined whether the June 2023 EMA/AIFA safety reminder coincided with an additional change in utilization.

Methods

This regional population-based drug-utilization study analysed reimbursed outpatient fluoroquinolone dispensing records among residents aged 0–14 years. Annual rates were expressed per 1000 pediatric residents; defined daily doses (DDDs) were secondary measures. Monthly dispensing-record rates were analysed by segmented interrupted time-series regression, using June 2023 as the interruption and Newey–West standard errors (maximum lag 3).

Results

Dispensing records fell from 786 in 2019 to 509 in 2024 (−35.2%), and standardized rates decreased from 1.51 to 1.08 per 1000 pediatric residents (−28.2%). DDD per 1000 residents decreased from 8.30 to 5.65. The estimated pre-reminder monthly slope was negative but not statistically significant (β = −0.000522; p = 0.305). Neither the immediate level change (β = +0.013316; p = 0.415) nor the post-reminder slope change (β = −0.000150; p = 0.852) was statistically significant. Results for all fluoroquinolones were robust to sensitivity analyses addressing seasonality and the COVID-19 pandemic; for ciprofloxacin, two exploratory specifications yielded nominally significant level increases.

Conclusions

Pediatric outpatient fluoroquinolone dispensing in Apulia decreased over six years, although its trajectory was not monotonic. The interrupted time-series analysis detected no statistically significant additional level or slope change following the June 2023 reminder. These findings describe utilization within an evolving regulatory and stewardship context but cannot establish the effects of earlier restrictions or assess the clinical appropriateness of individual dispensings.

Zitieren

APA

Aricò, M., Procacci, C., Stefanizzi, P., Palmieri, C., & Tafuri, S. (2026). Pediatric Outpatient Fluoroquinolone Dispensing After EMA/AIFA Safety Restrictions: A Regional Interrupted Time-Series Analysis from Southern Italy. Antibiotics, 15(11), 1151. https://doi.org/10.3390/antibiotics15111151

Vancouver

Aricò M, Procacci C, Stefanizzi P, Palmieri C, Tafuri S. Pediatric Outpatient Fluoroquinolone Dispensing After EMA/AIFA Safety Restrictions: A Regional Interrupted Time-Series Analysis from Southern Italy. Antibiotics. 2026;15(11):1151. doi:10.3390/antibiotics15111151

BibTeX
@article{Aric2026,
  author = {Aricò, Maurizio and Procacci, Cataldo and Stefanizzi, Pasquale and Palmieri, Claudia and Tafuri, Silvio},
  title = {Pediatric Outpatient Fluoroquinolone Dispensing After EMA/AIFA Safety Restrictions: A Regional Interrupted Time-Series Analysis from Southern Italy},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {1151},
  doi = {10.3390/antibiotics15111151}
}
Kostenlos starten →